Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial Cetuximab for Newly Diagnosed Glioblastoma
NCT02861898Phase 2Recruiting
- Sponsor
- Northwell Health
- Start
- Jun 2016
- Primary completion
- Dec 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in glioblastoma (GBM), sponsored by Northwell Health. Started Jun 2016; status: recruiting.
02
Drugs
cetuximab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02861898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02861898.